Navigation Links
FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis

Food and Drug Association as approved the drug CLARINEX-D 12 HOUR for use in treating symptoms of seasonal allergic rhinitis. // CLARINEX-D 12 HOUR is a drug containing a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP 120 mg. FDA has approved the drug for use in persons above 12 years of age. The drug has been found effective in curing persons with nasal and non-nasal symptoms occurring due to seasonal allergic rhinitis. Two clinical studies in 1,248 patients have found that the drug CLARINEX-D is found to be more effective in controlling allergic symptoms than the drug psueoephedrine alone.

The drug contains a delivery system, which delivers psudoephedrine in a consistent manner, and a dosage of two times a day of the nasal drug is found to be effective in controlling symptoms of allergic rhinitis and relieves nasal blockage and congestion, running nose, sneezing, watery eyes and itchy throat. The drug is found to be very effective in controlling allergic symptoms but has been found to be associated with mild side effects of insomnia, headache, pharyngitis, weakness and fatigue.


'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves surgical gel
3. FDA approves drug for rare liver disease
4. FDA approves first pocket-sized EKG machine
5. FDA approves Watson Pharmaceuticals Oxytrol patch
6. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
7. Madras High Court Disapproves of Comparative Advertisements
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. Old flu drugs not effective against seasonal influenza
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: